High Risk of ESRD in Type 1 Diabetes: Call for Action: Introduction

      Despite 30 years of significant improvements in the care of patients with type 1 diabetes (T1D), the risk of end-stage renal disease (ESRD) in these patients in the United States has increased rather than decreased, although it now occurs at slightly older ages. Furthermore, the competing risk of mortality from other causes (including cardiovascular disease) for patients with diabetic nephropathy has proved to be a relatively minor competitor. Therefore, ESRD has become the major contributor to the excess morbidity and premature mortality of patients with T1D. This state of affairs is a call to action and the rationale for this special issue of Seminars in Nephrology.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect